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Abstract Measures of interaction on an additive scale
(relative excess risk due to interaction [RERI], attributable
proportion [AP], synergy index [S]), were developed for
risk factors rather than preventive factors. It has been
suggested that preventive factors should be recoded to risk
factors before calculating these measures. We aimed to
show that these measures are problematic with preventive
factors prior to recoding, and to clarify the recoding
method to be used to circumvent these problems. Recoding
of preventive factors should be done such that the stratum
with the lowest risk becomes the reference category when
both factors are considered jointly (rather than one at a
time). We used data from a case-control study on the
interaction between ACE inhibitors and the ACE gene on
incident diabetes. Use of ACE inhibitors was a preventive
factor and DD ACE genotype was a risk factor. Before
recoding, the RERI, AP and S showed inconsistent results
(RERI = 0.26 [95%CI: -0.30; 0.82], AP = 0.30 [95%CI:
-0.28; 0.88], S = 0.35 [95%CI: 0.02; 7.38]), with the ﬁrst
two measures suggesting positive interaction and the third
negative interaction. After recoding the use of ACE
inhibitors, they showed consistent results (RERI =- 0.37
[95%CI: -1.23; 0.49], AP =- 0.29 [95%CI: -0.98; 0.40],
S = 0.43 [95%CI: 0.07; 2.60]), all indicating negative
interaction. Preventive factors should not be used to cal-
culate measures of interaction on an additive scale without
recoding.
Keywords Interaction   Preventive factors   Relative
excess risk due to interaction   Synergy index
Introduction
Interaction refers to the situation where the effect of one
exposure on a certain outcome is different across strata of
another exposure. This means that if interaction between
two exposures is present, these exposures are not inde-
pendent in causing a certain outcome. A classical example
is the interaction between smoking and asbestos on the risk
of lung cancer [1]. The presence and direction of interac-
tion depends on the scale, e.g. additive or multiplicative,
that is used. Interaction on an additive scale means that the
combined effect of two exposures is larger (or smaller)
than the sum of the individual effects of the two exposures,
whereas interaction on a multiplicative scale means that the
combined effect is larger (or smaller) than the product of
the individual effects. A number of epidemiologists have
argued that biologic interaction should be assessed on an
additive scale rather than a multiplicative scale [1–6].
Interaction on an additive scale can be calculated using
relative risks and different measures quantifying this
interaction have been described, such as the relative excess
risk due to interaction (RERI), the proportion attributable
to interaction (AP), and the synergy index (S) [7]. Provided
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measures can be used to assess interaction on an additive
scale even with case-control data. Moreover, methods to
calculate conﬁdence intervals around these measures have
been developed [8–10], and methods to quantify interaction
on an additive scale in the case of continuous determinants
have been presented [11].
The measures quantifying interaction on an additive
scale were developed to use with exposures that are risk
factors rather than preventive factors. Risk factors meaning
that the relative risk of the factor with the outcome is larger
than 1, and preventive factors meaning that the relative risk
of the factor with the outcome is smaller than 1. It is not
commonly known that these measures should only be
applied to risk factors (see for example [12–15]). Rothman
proposed, in case of preventive factors, to choose the high-
risk category of each exposure to be the exposed category
[1]. This method turns the preventive factor into a risk
factor by considering absence of the preventive to be the
cause. Empirical examples of this method, however, are
lacking. Moreover, it is unclear from Rothman’s descrip-
tion and similar description that have followed his [16]
whether this recoding should be done one factor at a time
or by selecting a reference category when both factors
considered jointly.
Our objectives were to show what happens if estimates
of measures of interaction on an additive scale are calcu-
lated with preventive factors instead of risk factors using an
example dataset, and to clarify the method of recoding of
preventive factors.
Methods
Example dataset
The empirical dataset that we used for illustration com-
prised a nested case-control study including 205 cases of
incident diabetes and 2,050 controls [17]. One of the aims
of the study was to examine whether the ACE insertion/
deletion gene modiﬁed the effect of the use of ACE
inhibitors on the risk of incident diabetes. For simplicity,
we combined past and current use of ACE inhibitors.
Homozygous for the deletion gene in the ACE gene will be
referred to as the DD genotype of the ACE gene, and
homozygous or heterozygous for the insertion gene of the
ACE gene will be referred to as the II or ID genotype of the
ACE gene.
Measures of interaction on an additive scale
For two dichotomous factors A and B: RRA?B? is the
relative risk of disease if both factors A and B are present,
RRA?B- is the relative risk of disease if factor A is present
but factor B is absent, RRA-B? is the relative risk of disease
if factor A is absent but factor B is present.
1. Relative excess risk due to interaction (part of the total
effect that is due to interaction):
RERI ¼ RRAþBþ   RRAþB    RRA Bþ þ 1
RERI = 0 means no interaction or exactly additivity;
RERI[0 means positive interaction or more than addi-
tivity; RERI\0 means negative interaction or less than
additivity; RERI can go from - inﬁnity to ? inﬁnity.
2. Proportion attributable to interaction (proportion of the
combined effect that is due to interaction):
AP ¼
RERI
RRAþBþ
AP = 0 means no interaction or exactly additivity; AP[0
means positive interaction or more than additivity; AP\0
means negative interaction or less than additivity; AP can
go from -1t o?1.
3. Synergy index (ratio between combined effect and
individual effects):
S ¼
RRAþBþ   1
RRAþB    1 ðÞ þ RRA Bþ   1 ðÞ
S = 1 means no interaction or exactly additivity; S[1
means positive interaction or more than additivity; S\1
means negative interaction or less than additivity; S can go
from 0 to inﬁnity.
Method of recoding
We show in the ‘‘Appendix’’ that if the category with the
lowest risk when both factors are considered together is
selected as the reference category then all three measures
of additive interaction will always agree. We also given a
numerical example in the ‘‘Appendix’’ that shows that if
decisions about recoding are made one factor at a time by
selecting the category with the lowest risk as the reference
group then the three measures of additive interaction may
diverge and one may calculate a negative value of the
synergy index.
Analyses
First, we calculated the odds ratio of the use of ACE
inhibitors on the risk of diabetes, and the odds ratio of the
DD genotype of the ACE gene on the risk of diabetes.
These odds ratios represent the effect of one of the expo-
sures analyzed without conditioning on the other exposure.
We refer to these effects as ‘single effects’. Subsequently,
we calculated joint effects of the use of ACE inhibitors and
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123the DD genotype of the ACE gene using one reference
category.
Second, we calculated the three measures of interaction
on an additive scale (RERI, AP, and S) and their 95%
conﬁdence intervals using the delta method [9], assuming
that the odds ratios calculated in the example dataset
approximated relative risks. We also calculated 95% con-
ﬁdence intervals using the method described by Zou [18],
which resulted in similar conﬁdence intervals.
Third, we recoded the variables in such a way that the
stratum with the lowest risk, when both factors are con-
sidered jointly, became the reference category. We calcu-
lated the measures of additive interaction again and
compared the results with the original results.
Because we used the data for illustration purposes only,
we did not take into account the matching of cases and
controls, and we did not adjust for potential confounders.
Results
Before recoding use of ACE inhibitors or DD genotype
of ACE gene
Table 1 presents the effect of the use of ACE inhibitors on
the risk of diabetes irrespective of the value of the ACE
gene, and the effect of the DD genotype of the ACE gene
on the risk of diabetes irrespective of the value of the use of
ACE inhibitors. Furthermore, the joint effects of the use of
ACE inhibitors and the DD genotype of the ACE gene
using one reference category (no use of ACE inhibitors and
II or ID genotype of the ACE gene) are presented. Use of
ACE inhibitors was a preventive factor for diabetes
(OR = 0.76 [95%CI: 0.57–1.03]), while the DD genotype
of the ACE gene was a small risk factor for diabetes
(OR = 1.03 [95%CI: 0.75–1.41]). However, when both
factors were considered jointly, then in the absence of use
of ACE inhibitors, the DD genotype of the ACE gene was a
preventive factor for diabetes (OR = 0.90 [95%CI:
0.61–1.34]).
The relative excess risk due to interaction on an additive
scale is 0.26 (95%CI: -0.30; 0.82), meaning that the
combined effect is 0.26 more than the sum of the individual
effects. One arrives at this 0.26 by calculating the differ-
ence between the expected combined effect (30% plus 10%
risk reduction would suggest 40% risk reduction when both
exposures are present) and the observed combined effect
(14% risk reduction). The synergy index is below 1 indi-
cating negative interaction, while the relative excess risk
due to interaction and the proportion attributable to the
interaction are both above 0 indicating positive interaction.
So, the different measures give inconsistent results indi-
cating that this is not the proper way to calculate these
measures.
Recoding use of ACE inhibitors
The OR was lowest in the stratum of ‘use of ACE inhibi-
tors and ACE gene II or ID’ (Table 1;O R= 0.70 [95%CI:
0.49–1.00]). To make this stratum the reference category,
we recoded the variable ‘use of ACE inhibitors’, so ‘no use
of ACE inhibitors’ was coded as 1 and ‘use of ACE
inhibitors’ as 0. Table 2 presents the results after recoding
the use of ACE inhibitors and shows that both individual
Table 1 Use of ACE inhibitors and DD genotype of ACE gene as preventive and risk factor for diabetes: effects of both exposures irrespective
of the value of the other exposure, joint effects of both exposures using one reference category, and measures of interaction on additive scale
N cases N controls Estimate 95% conﬁdence interval
Lower limit Upper limit
Odds ratios representing single effects
No use of ACE inhibitors 129 1,167 1.00 (reference)
Use of ACE inhibitors 74 877 0.76 0.57 1.03
ACE gene II or ID 144 1,462 1.00 (reference)
ACE gene DD 59 582 1.03 0.75 1.41
Odds ratios representing joint effects
No use of ACE inhibitors and ACE gene II or ID 90 788 1.00 (reference)
Use of ACE inhibitors and ACE gene II or ID 54 674 0.70 0.49 1.00
No use of ACE inhibitors and ACE gene DD 39 379 0.90 0.61 1.34
Use of ACE inhibitors and ACE gene DD 20 203 0.86 0.52 1.43
Measures of interaction on additive scale
RERI 0.26 -0.30 0.82
AP 0.30 -0.28 0.88
S 0.35 0.02 7.36
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123effects are indicating risks of diabetes (OR = 1.43 for no
use of ACE inhibitors; OR = 1.23 for DD genotype of
ACE gene). The RERI, AP and synergy index now give
consistent results as they all indicate negative interaction
on an additive scale, meaning that the combined effect is
less than the sum of the effects of not using ACE inhibitors
and having the DD genotype of the ACE gene. Note that
not only the sign of the RERI and AP changed, but also the
estimate itself.
Explaining the differences
The reason why using preventive factors gives wrong and
inconsistent results in the measures of interaction on an
additive scale is because a relative risk is restricted
between 0 and 1 for a preventive factor while it can go
from 1 to inﬁnity for a risk factor. For example, a relative
risk of 0.60 means a relative risk reduction of 40%,
whereas the inverse (1/0.60 = 1.67) means a relative
increase in risk of 67%. Clearly, this could lead to different
results if these numbers are used in calculating the mea-
sures of additive interaction (e.g. the denominator in the
synergy index S could be negative).
Discussion
In this study we showed that calculating measures of
interaction on an additive scale using preventive factors
can give inconsistent results. Researchers should therefore
be aware to not use preventive factors to calculate these
measures unless they have been recoded. After recoding
exposures, careful thought about the interpretation of the
measure of interaction is needed as the exposure is changed
to its opposite, e.g., physical inactivity rather than physical
activity, or continued smoking instead of smoking cessa-
tion, and this of course has to be taken into account in the
interpretation of the interaction.
Recoding of preventive factors is a pragmatic solution to
calculate the correct measures of interaction on an additive
scale. When measures of additive interaction are of inter-
est, this recoding of the variables should be done in such a
way that the stratum with the lowest risk when both factors
are considered jointly becomes the reference category. The
result of this recoding is that the individual effects (the
effect of one of the exposures in the absence of the other
exposure) become risk factors for the outcome. This is
important because these individual effect estimates are
used in the formulas for calculating interaction on an
additive scale. In particular, by choosing the stratum with
the lowest risk (when both factors are considered jointly) as
the reference category it is ensured that after recoding the
presence of each factor will have a non-negative effect in
the absence of the other so that all of the measures of
interaction can be appropriately interpreted. If factors are
recoded one at a time (rather than jointly as we suggest),
this can again result in inconsistent effect measures. It was
unclear in prior literature whether factors should be reco-
ded one at a time or when considered jointly; the previous
descriptions [1, 16] are ambiguous and if anything read as
though the recoding should be done one factor at a time.
We have shown that recoding should be done by consid-
ering both factors jointly.
The focus of the recoding method we have described
here has been to ensure that all three measures of additive
interaction (RERI, AP and S) give consistent results with
Table 2 No use of ACE
inhibitors and DD genotype of
ACE gene as risk factors for
diabetes after recoding use of
ACE inhibitors: single effects of
both exposures, joint effects
when using one reference
category, and measures of
interaction on additive scale
Estimate 95% conﬁdence interval
Lower limit Upper limit
Odds ratios representing single effects
Use of ACE inhibitors 1.00 (reference)
No use of ACE inhibitors 1.31 0.97 1.77
ACE gene II or ID 1.00 (reference)
ACE gene DD 1.03 0.75 1.41
Odds ratios representing joint effects
No use of ACE inhibitors and ACE gene II or ID 1.43 1.00 2.03
Use of ACE inhibitors and ACE gene II or ID 1.00 (reference)
No use of ACE inhibitors and ACE gene DD 1.28 0.84 1.98
Use of ACE inhibitors and ACE gene DD 1.23 0.72 2.10
Measures of interaction on additive scale
RERI -0.37 -1.23 0.49
AP -0.29 -0.98 0.40
S 0.43 0.07 2.60
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additive scale. When inference about certain forms of
antagonism are in view, alternative recoding schemes will
be of interest [19].
The recoding described here can also be motivated by
considerations of the interpretation of the interaction
measures themselves. The acronym RERI stands for the
‘‘Relative Excess Risk due to Interaction.’’ This may be
seen as a reasonable description of this measure because
the measure itself can be rewritten as: RERI ¼ RRAþBþ  
RRAþB    RRA Bþ þ 1 and thus indicates the extent to
which the relative excess risk (the extent to which the risk
exceeds 1) when both factors are present is greater than the
sum of the relative excess risks for each of the factors
individually in the absence. This difference in the relative
excess risks is ‘‘due to interaction.’’ If, however, one of the
factors is preventive in the absence of the other (i.e. if one
of RRA?B- or RRA-B? are less than 1) then it is no longer
clear in what sense the description ‘‘relative excess risk
due to interaction’’ is reasonable. It may be that
RRA?B?= 1 and that the measure RERI ¼ RRAþBþ  
RRAþB   RRA Bþ þ 1 is greater than 0 simply because
one of the factors is preventive. The measure RERI only
merits an interpretation as a ‘‘relative excess risk due to
interaction’’ when neither factor is preventive. Some
authors now thus refer to the measure as the Interaction
Contrast Ratio [20].
Likewise the synergy index for additivity S ¼
RRAþBþ 1
RRAþB  1 ðÞ þ RRA Bþ 1 ðÞ only merits the interpretation as a
ratio measure for assessing relative excess risk if neither
factor is preventive. The method of recoding we have
described here ensures that RERI and S will always carry
the interpretation of relative excess measures.
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Appendix
Proof that choosing the category with the lowest risk when
both factors are considered jointly as the reference category
will give consistent results among the three measures of
additive interaction.
Clearly, RERI[0 if and only if AP[0 since AP ¼
RERI
RRAþBþ and likewise RERI\0 if and only if AP\0. If the
factors are recoded so that the category with the lowest risk
when both factors are considered jointly is selected as the
reference category then we will have that RRA?B- C 0 and
RRA-B?C0. When RRA?B- C 0 and RRA-B?C0, we have
that S[1 if and only if
RRAþBþ 1
ðRRAþB  1ÞþðRRA Bþ 1Þ[1 which
holds if and only if RRAþBþ   1[ðRRAþB    1Þþ
ðRRA Bþ   1Þwhich holds if and only if RERI ¼
RRAþBþ   RRAþB    RRA Bþ þ 1[0. And similarly,
with RRA?B- C 0 and RRA-B?C0, we have that S\1i f
and only if RERI\0.
Example demonstrating that if recoding is done one
factor at a time rather than jointly, the three measures of
additive interaction may disagree and S may be negative.
Consider a case control study with two dichotomous
factors (G and E) with 600 individuals with E = 0, G = 1,
600 with E = 0, G = 1, 200 with E = 1, G = 0 and 200
with E = 1, G = 1 with the number of cases and controls
in each category reported below.
N cases N controls OR
Odds ratios representing joint effects
E = 0, G = 0 48 552 1.00 (reference)
E = 0, G = 1 66 534 1.42
E = 1, G = 0 12 188 0.73
E = 1, G = 1 6 194 0.36
Odds ratios representing single effects
E = 0 114 1,086 1.00 (reference)
E = 1 18 382 0.45
G = 0 60 540 1.00 (reference)
G = 1 72 528 1.23
If the factors were recoded one at a time then we would
choose E = 1 as the reference category for E as the OR for
E = 1 is 0.45 and we would choose G = 0 as the reference
category for G since the OR for G = 1 is 1.23. If the
factors are recoded jointly then we see that E = 1, G = 1
is the category with the lowest odds and so E = 1 would be
chosen as the reference category for E and G = 1 would be
chosen as the reference category for G.
If we proceeded by recoding the factors one at a time so
that the reference category A- was E = 1 and the
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following odds ratios:
N cases N controls OR
Odds ratios representing joint effects
A - B - (E = 1, G = 0) 12 188 1.00 (reference)
A - B ? (E = 1, G = 1) 6 194 0.48
A ? B - (E = 0, G = 0) 48 552 1.36
A ? B ? (E = 0, G = 1) 66 534 1.94
Here we would obtain a synergy index of:
RRAþBþ 1
ðRRAþB  1ÞþðRRA Bþ 1Þ ¼ 1:94 1
ð1:36 1Þþð0:48 1Þ ¼  5:86.Thesyn-
ergy index is negative. With the coding in the Table above
RERI = 1.1 and AP = 0.57.
If instead we proceed by recoding the factors jointly by
choosing the combined category with the lowest risk as the
reference so that the reference category A- was E = 1 and
the reference category B- was G = 1, we would obtain the
following odds ratios:
N cases N controls OR
Odds ratios representing joint effects
A - B - (E = 1, G = 1) 6 194 1.00 (reference)
A - B ? (E = 1, G = 0) 12 188 2.06
A ? B - (E = 0, G = 1) 66 534 3.93
A ? B ? (E = 0, G = 0) 48 552 2.81
Now we obtain a value of the synergy index within the
range from 0 to inﬁnity:
RRAþBþ 1
ðRRAþB  1ÞþðRRA Bþ 1Þ ¼ 2:81 1
ð3:93 1Þþð2:06 1Þ ¼ 0:45. The
value of S\1 indicates a negative interaction which is in
agreement with what is indicated by RERI =- 2.18\0
and AP =- 0.76\0.
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